Cargando…
Synergy between Proteasome Inhibitors and Imatinib Mesylate in Chronic Myeloid Leukemia
BACKGROUND: Resistance developed by leukemic cells, unsatisfactory efficacy on patients with chronic myeloid leukemia (CML) at accelerated and blastic phases, and potential cardiotoxity, have been limitations for imatinib mesylate (IM) in treating CML. Whether low dose IM in combination with agents...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2705802/ https://www.ncbi.nlm.nih.gov/pubmed/19606213 http://dx.doi.org/10.1371/journal.pone.0006257 |
_version_ | 1782169030900056064 |
---|---|
author | Hu, Zheng Pan, Xiao-Fen Wu, Fu-Qun Ma, Li-Yuan Liu, Da-Peng Liu, Ying Feng, Ting-Ting Meng, Fan-Yi Liu, Xiao-Li Jiang, Qian-Li Chen, Xiao-Qin Liu, Jing-Lei Liu, Ping Chen, Zhu Chen, Sai-Juan Zhou, Guang-Biao |
author_facet | Hu, Zheng Pan, Xiao-Fen Wu, Fu-Qun Ma, Li-Yuan Liu, Da-Peng Liu, Ying Feng, Ting-Ting Meng, Fan-Yi Liu, Xiao-Li Jiang, Qian-Li Chen, Xiao-Qin Liu, Jing-Lei Liu, Ping Chen, Zhu Chen, Sai-Juan Zhou, Guang-Biao |
author_sort | Hu, Zheng |
collection | PubMed |
description | BACKGROUND: Resistance developed by leukemic cells, unsatisfactory efficacy on patients with chronic myeloid leukemia (CML) at accelerated and blastic phases, and potential cardiotoxity, have been limitations for imatinib mesylate (IM) in treating CML. Whether low dose IM in combination with agents of distinct but related mechanisms could be one of the strategies to overcome these concerns warrants careful investigation. METHODS AND FINDINGS: We tested the therapeutic efficacies as well as adverse effects of low dose IM in combination with proteasome inhibitor, Bortezomib (BOR) or proteasome inhibitor I (PSI), in two CML murine models, and investigated possible mechanisms of action on CML cells. Our results demonstrated that low dose IM in combination with BOR exerted satisfactory efficacy in prolongation of life span and inhibition of tumor growth in mice, and did not cause cardiotoxicity or body weight loss. Consistently, BOR and PSI enhanced IM-induced inhibition of long-term clonogenic activity and short-term cell growth of CML stem/progenitor cells, and potentiated IM-caused inhibition of proliferation and induction of apoptosis of BCR-ABL+ cells. IM/BOR and IM/PSI inhibited Bcl-2, increased cytoplasmic cytochrome C, and activated caspases. While exerting suppressive effects on BCR-ABL, E2F1, and β-catenin, IM/BOR and IM/PSI inhibited proteasomal degradation of protein phosphatase 2A (PP2A), leading to a re-activation of this important negative regulator of BCR-ABL. In addition, both combination therapties inhibited Bruton's tyrosine kinase via suppression of NFκB. CONCLUSION: These data suggest that combined use of tyrosine kinase inhibitor and proteasome inhibitor might be helpful for optimizing CML treatment. |
format | Text |
id | pubmed-2705802 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-27058022009-07-16 Synergy between Proteasome Inhibitors and Imatinib Mesylate in Chronic Myeloid Leukemia Hu, Zheng Pan, Xiao-Fen Wu, Fu-Qun Ma, Li-Yuan Liu, Da-Peng Liu, Ying Feng, Ting-Ting Meng, Fan-Yi Liu, Xiao-Li Jiang, Qian-Li Chen, Xiao-Qin Liu, Jing-Lei Liu, Ping Chen, Zhu Chen, Sai-Juan Zhou, Guang-Biao PLoS One Research Article BACKGROUND: Resistance developed by leukemic cells, unsatisfactory efficacy on patients with chronic myeloid leukemia (CML) at accelerated and blastic phases, and potential cardiotoxity, have been limitations for imatinib mesylate (IM) in treating CML. Whether low dose IM in combination with agents of distinct but related mechanisms could be one of the strategies to overcome these concerns warrants careful investigation. METHODS AND FINDINGS: We tested the therapeutic efficacies as well as adverse effects of low dose IM in combination with proteasome inhibitor, Bortezomib (BOR) or proteasome inhibitor I (PSI), in two CML murine models, and investigated possible mechanisms of action on CML cells. Our results demonstrated that low dose IM in combination with BOR exerted satisfactory efficacy in prolongation of life span and inhibition of tumor growth in mice, and did not cause cardiotoxicity or body weight loss. Consistently, BOR and PSI enhanced IM-induced inhibition of long-term clonogenic activity and short-term cell growth of CML stem/progenitor cells, and potentiated IM-caused inhibition of proliferation and induction of apoptosis of BCR-ABL+ cells. IM/BOR and IM/PSI inhibited Bcl-2, increased cytoplasmic cytochrome C, and activated caspases. While exerting suppressive effects on BCR-ABL, E2F1, and β-catenin, IM/BOR and IM/PSI inhibited proteasomal degradation of protein phosphatase 2A (PP2A), leading to a re-activation of this important negative regulator of BCR-ABL. In addition, both combination therapties inhibited Bruton's tyrosine kinase via suppression of NFκB. CONCLUSION: These data suggest that combined use of tyrosine kinase inhibitor and proteasome inhibitor might be helpful for optimizing CML treatment. Public Library of Science 2009-07-16 /pmc/articles/PMC2705802/ /pubmed/19606213 http://dx.doi.org/10.1371/journal.pone.0006257 Text en Hu et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Hu, Zheng Pan, Xiao-Fen Wu, Fu-Qun Ma, Li-Yuan Liu, Da-Peng Liu, Ying Feng, Ting-Ting Meng, Fan-Yi Liu, Xiao-Li Jiang, Qian-Li Chen, Xiao-Qin Liu, Jing-Lei Liu, Ping Chen, Zhu Chen, Sai-Juan Zhou, Guang-Biao Synergy between Proteasome Inhibitors and Imatinib Mesylate in Chronic Myeloid Leukemia |
title | Synergy between Proteasome Inhibitors and Imatinib Mesylate in Chronic Myeloid Leukemia |
title_full | Synergy between Proteasome Inhibitors and Imatinib Mesylate in Chronic Myeloid Leukemia |
title_fullStr | Synergy between Proteasome Inhibitors and Imatinib Mesylate in Chronic Myeloid Leukemia |
title_full_unstemmed | Synergy between Proteasome Inhibitors and Imatinib Mesylate in Chronic Myeloid Leukemia |
title_short | Synergy between Proteasome Inhibitors and Imatinib Mesylate in Chronic Myeloid Leukemia |
title_sort | synergy between proteasome inhibitors and imatinib mesylate in chronic myeloid leukemia |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2705802/ https://www.ncbi.nlm.nih.gov/pubmed/19606213 http://dx.doi.org/10.1371/journal.pone.0006257 |
work_keys_str_mv | AT huzheng synergybetweenproteasomeinhibitorsandimatinibmesylateinchronicmyeloidleukemia AT panxiaofen synergybetweenproteasomeinhibitorsandimatinibmesylateinchronicmyeloidleukemia AT wufuqun synergybetweenproteasomeinhibitorsandimatinibmesylateinchronicmyeloidleukemia AT maliyuan synergybetweenproteasomeinhibitorsandimatinibmesylateinchronicmyeloidleukemia AT liudapeng synergybetweenproteasomeinhibitorsandimatinibmesylateinchronicmyeloidleukemia AT liuying synergybetweenproteasomeinhibitorsandimatinibmesylateinchronicmyeloidleukemia AT fengtingting synergybetweenproteasomeinhibitorsandimatinibmesylateinchronicmyeloidleukemia AT mengfanyi synergybetweenproteasomeinhibitorsandimatinibmesylateinchronicmyeloidleukemia AT liuxiaoli synergybetweenproteasomeinhibitorsandimatinibmesylateinchronicmyeloidleukemia AT jiangqianli synergybetweenproteasomeinhibitorsandimatinibmesylateinchronicmyeloidleukemia AT chenxiaoqin synergybetweenproteasomeinhibitorsandimatinibmesylateinchronicmyeloidleukemia AT liujinglei synergybetweenproteasomeinhibitorsandimatinibmesylateinchronicmyeloidleukemia AT liuping synergybetweenproteasomeinhibitorsandimatinibmesylateinchronicmyeloidleukemia AT chenzhu synergybetweenproteasomeinhibitorsandimatinibmesylateinchronicmyeloidleukemia AT chensaijuan synergybetweenproteasomeinhibitorsandimatinibmesylateinchronicmyeloidleukemia AT zhouguangbiao synergybetweenproteasomeinhibitorsandimatinibmesylateinchronicmyeloidleukemia |